People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amunix Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $203.9M | $3.9B | 2020 |
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2011 |
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.6M | 2021 |
| Millendo Therapeutics, Inc. | — | Pharmaceuticals | Series C | $106.5M | $1.8B | 2017 |
| Allena Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $80.5M | $75.0M | 2014 |
| ProNAi Therapeutics Inc | — | Biotechnology | Series C | $77.7M | $2.4B | 2014 |
| Alcresta Therapeutics, Inc. | — | Biotechnology | Series C | $75.9M | $409.6M | 2016 |
| Calistoga Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $60.3M | $850.1M | 2009 |
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2015 |
| Incline Therapeutics, Inc. | — | Biotechnology | Series B | $43.9M | $853.3M | 2009 |
| ChanRx Corp. | — | Pharmaceuticals | Series B | $22.1M | $563.6M | 2011 |
| Merganser Biotech, Inc. | — | Biotechnology | Series A | $21.1M | $473.5M | 2015 |
James Topper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Topper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carol Gallagher | 3 | 6 |
| Stephen Kraus | 2 | 7 |
| Alexey Margolin | 2 | 3 |
| Garheng Kong | 1 | 16 |
| Peter Thompson | 1 | 16 |
| David Hirsch | 1 | 16 |
| Jerel Davis | 1 | 13 |
| Shelley Chu | 1 | 10 |
| Russell Hirsch | 1 | 10 |
| Heath Lukatch | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Ed Hurwitz | 1 | 9 |
| Albert Cha | 1 | 9 |
| Kevin Lalande | 1 | 8 |
| Richard Lin | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Jay Lichter | 1 | 7 |
| Tighe Reardon | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| Andrew J. Schwab | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.